NEUROCRINE BIOSCIENCES INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NEUROCRINE BIOSCIENCES INC (NBIX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $65.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $65.00M, a 23.11% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $57.20M, a 8.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $58.60M, a 11.75% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $53.70M, a 29.40% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $217.90M, a 11.46% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $195.50M, a 0.62% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $194.30M, a 12.25% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $173.10M, a 28.99% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $65.00M 10-Q · filed 2026-07-31 | $122.20M 10-Q · filed 2026-07-31 | $180.80M derived: sum of 3 quarters · filed 2026-07-31 | $234.50M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $57.20M 10-Q · filed 2026-05-05 | $115.80M derived: sum of 2 quarters · filed 2026-05-05 | $169.50M derived: sum of 3 quarters · filed 2026-05-05 | $222.30M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-12-31 | $58.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $112.30M derived: sum of 2 quarters · filed 2026-02-11 | $165.10M derived: sum of 3 quarters · filed 2026-07-31 | $217.90M 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $53.70M 10-Q · filed 2025-10-28 | $106.50M derived: sum of 2 quarters · filed 2026-07-31 | $159.30M 10-Q · filed 2025-10-28 | $225.70M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-06-30 | $52.80M 10-Q · filed 2026-07-31 | $105.60M 10-Q · filed 2026-07-31 | $172.00M derived: sum of 3 quarters · filed 2026-07-31 | $213.50M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $52.80M 10-Q · filed 2026-05-05 | $119.20M derived: sum of 2 quarters · filed 2026-05-05 | $160.70M derived: sum of 3 quarters · filed 2026-05-05 | $203.80M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $66.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $107.90M derived: sum of 2 quarters · filed 2026-02-11 | $151.00M derived: sum of 3 quarters · filed 2026-02-11 | $195.50M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $41.50M 10-Q · filed 2025-10-28 | $84.60M derived: sum of 2 quarters · filed 2025-10-28 | $129.10M 10-Q · filed 2025-10-28 | $167.20M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $43.10M 10-Q · filed 2025-07-30 | $87.60M 10-Q · filed 2025-07-30 | $125.70M derived: sum of 3 quarters · filed 2026-02-11 | $173.50M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $44.50M 10-Q · filed 2025-05-05 | $82.60M derived: sum of 2 quarters · filed 2026-02-11 | $130.40M derived: sum of 3 quarters · filed 2026-02-11 | $198.90M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $85.90M derived: sum of 2 quarters · filed 2026-02-11 | $154.40M derived: sum of 3 quarters · filed 2026-02-11 | $194.30M 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $47.80M 10-Q · filed 2024-10-30 | $116.30M derived: sum of 2 quarters · filed 2024-10-30 | $156.20M 10-Q · filed 2024-10-30 | $199.70M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-06-30 | $68.50M 10-Q · filed 2024-08-01 | $108.40M 10-Q · filed 2024-08-01 | $151.90M derived: sum of 3 quarters · filed 2025-02-10 | $195.00M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-03-31 | $39.90M 10-Q · filed 2024-05-01 | $83.40M derived: sum of 2 quarters · filed 2025-02-10 | $126.50M derived: sum of 3 quarters · filed 2025-02-10 | $176.00M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2022-12-31 | $43.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $86.60M derived: sum of 2 quarters · filed 2025-02-10 | $136.10M derived: sum of 3 quarters · filed 2025-02-10 | $173.10M 10-K · filed 2025-02-10 | ||
| 2022-09-30 | $43.10M 10-Q · filed 2023-10-31 | $92.60M derived: sum of 2 quarters · filed 2023-10-31 | $129.60M 10-Q · filed 2023-10-31 | $165.20M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | $49.50M 10-Q · filed 2023-08-01 | $86.50M 10-Q · filed 2023-08-01 | $122.10M derived: sum of 3 quarters · filed 2024-02-09 | $159.20M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $37.00M 10-Q · filed 2023-05-03 | $72.60M derived: sum of 2 quarters · filed 2024-02-09 | $109.70M derived: sum of 3 quarters · filed 2024-02-09 | $138.30M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $35.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $72.70M derived: sum of 2 quarters · filed 2024-02-09 | $101.30M derived: sum of 3 quarters · filed 2024-02-09 | $134.20M 10-K · filed 2024-02-09 | ||
| 2021-09-30 | $37.10M 10-Q · filed 2022-11-01 | $65.70M derived: sum of 2 quarters · filed 2022-11-01 | $98.60M 10-Q · filed 2022-11-01 | $119.60M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-06-30 | $28.60M 10-Q · filed 2022-08-04 | $61.50M 10-Q · filed 2022-08-04 | $82.50M derived: sum of 3 quarters · filed 2023-02-09 | $109.20M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-03-31 | $32.90M 10-Q · filed 2022-05-04 | $53.90M derived: sum of 2 quarters · filed 2023-02-09 | $80.60M derived: sum of 3 quarters · filed 2023-02-09 | $110.10M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2020-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $47.70M derived: sum of 2 quarters · filed 2023-02-09 | $77.20M derived: sum of 3 quarters · filed 2023-02-09 | $100.00M 10-K · filed 2023-02-09 | ||
| 2020-09-30 | $26.70M 10-Q · filed 2021-11-01 | $56.20M derived: sum of 2 quarters · filed 2021-11-01 | $79.00M 10-Q · filed 2021-11-01 | $100.30M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2020-06-30 | $29.50M 10-Q · filed 2021-08-03 | $52.30M 10-Q · filed 2021-08-03 | $73.60M derived: sum of 3 quarters · filed 2022-02-11 | $93.90M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2020-03-31 | $22.80M 10-Q · filed 2021-05-05 | $44.10M derived: sum of 2 quarters · filed 2022-02-11 | $64.40M derived: sum of 3 quarters · filed 2022-02-11 | $82.30M derived: sum of 4 quarters · filed 2022-02-11 | ||
| 2019-12-31 | $21.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $41.60M derived: sum of 2 quarters · filed 2022-02-11 | $59.50M derived: sum of 3 quarters · filed 2022-02-11 | $75.30M 10-K · filed 2022-02-11 | $75.26M 10-K · filed 2020-02-07 | |
| 2019-09-30 | $20.30M 10-Q · filed 2020-11-09 | $20.25M 10-Q · filed 2019-11-04 | $38.20M derived: sum of 2 quarters · filed 2020-11-09 | $54.00M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $17.90M 10-Q · filed 2020-08-03 | $17.93M 10-Q · filed 2019-07-29 | $33.70M 10-Q · filed 2020-08-03 | |||
| 2019-03-31 | $15.80M 10-Q · filed 2020-05-06 | $15.76M 10-Q · filed 2019-04-29 | ||||
| 2018-12-31 | $58.10M 10-K · filed 2021-02-05 | $58.07M 10-K · filed 2019-02-08 | ||||
| 2018-09-30 | $13.07M 10-Q · filed 2019-11-04 | $24.92M derived: sum of 2 quarters · filed 2019-11-04 | $44.80M derived: sum of 3 quarters · filed 2019-11-04 | |||
| 2018-06-30 | $11.85M 10-Q · filed 2019-11-04 | $31.73M derived: sum of 2 quarters · filed 2019-11-04 | ||||
| 2018-03-31 | $19.88M 10-Q · filed 2019-11-04 | |||||
| 2017-12-31 | $42.52M 10-K · filed 2020-02-07 | |||||
| 2016-12-31 | $28.46M 10-K · filed 2019-02-08 | |||||
| 2015-12-31 | $28.39M 10-K · filed 2018-02-13 | |||||
| 2014-12-31 | $10.38M 10-K · filed 2017-02-14 | |||||
| 2013-12-31 | $6.82M 10-K · filed 2016-02-11 | |||||
| 2012-12-31 | $5.48M 10-K · filed 2015-02-09 | |||||
| 2011-12-31 | $2.92M 10-K · filed 2014-02-11 | |||||
| 2010-12-31 | $3.13M 10-K · filed 2013-02-08 | |||||
| 2009-12-31 | $5.54M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |